Drug Trial Radar · NCT06868849
A Study of JMT203 in Patients With Cancer Cachexia
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
307
Planned (sponsor's estimate)
Start
May 15, 2024
Primary completion
Aug 14, 2027
Study completion May 15, 2029
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
Conditions
- Non Small Cell Lung Cancer
- Pancreatic Cancer
- Cancer Cachexia
- Colorectal Cancer Cachexia
- Pancreatic Cancer Cachexia
Interventions
JMT203 InjectionDrug
Drug:JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).
JMT203 InjectionDrug
Drug:JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).Time frame: Up to 90 days after the last dose of JMT203
- Phase Ia: Incidence of dose-limiting toxicity (DLT) eventsTime frame: Up to 21 days after the first dose of JMT203
- Phase Ia: MTD (if applicable).Time frame: Up to 90 days post last dose
- Phase Ia: RDE.Time frame: Up to 90 days post last dose
- Phase Ib: Average change in body weight from baseline at each assessment timepoint within 12 weeks.Time frame: Within 12 weeks from baseline
- Phase II: RP3DTime frame: Approximately 1 year from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sir run run shaw Hospital
Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.